BioMedical Enterprises, Inc. (BME) has appointed Kenneth I. Moch as its president and chief executive officer (CEO). Moch has served as the president of Euclidean Life Science Advisors, since early 2008. He previously was managing director, Healthcare Investment Banking at ThinkEquity Partners and chairman, president and CEO of Alteon, Inc. W. Casey Fox, BME’s founder, will become chief technology officer and continue to focus his efforts on building BME’s innovative product offerings.
Moch earlier served as President and CEO of Biocyte Corporation, the cellular therapy company that pioneered the collection and commercial application of cord blood stem cells, and as a management consultant with McKinsey & Company, Inc. Moch holds a degree in biochemistry from Princeton University and an MBA from the Stanford Graduate School of Business.
“Ken is a proven leader who brings extensive senior management and operational experience to BME, as well as a shared strategic vision to create a leading medical device company,” said Richard M. Johnston, chairman of BME and Managing Member of Camden Partners Holdings, LLC.
“It is a privilege to be joining BME at this exciting time in the company’s history,” said Moch. “I believe that BME’s unique technology and innovative products have tremendous commercial growth potential. Together with BME’s talented employees, I look forward to accelerating the growth of the Company and broadening the use of our novel memory metal implants.”
“Ken’s involvement is a statement to our distributor partners that we intend to grow our business for our mutual benefit. With in-house manufacturing now on line at BME we have the capability, support and focus for new product development and the continued improvement of our product lines,” said Casey Fox.